AMRI, Metrion Biosciences team up to provide ion channel drug discovery services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/selvanegra)
(Image: Getty/selvanegra)

Related tags: Amri, Metrion Biosciences, Drug discovery, Contract research organisation, Contract research, Ion channel

The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.

The contract research, development, and manufacturing organization (CDMO) AMRI ​has aligned with Metrion Biosciences​, a specialist ion channel contract research organization (CRO) and drug discovery company.

Under the collaboration agreement, AMRI will offer its clients access to Metrion's portfolio of assay tools and technologies for ion channel screening, cardiac safety profiling, and neuroscience applications.

In turn, Metrion customers will gain access to AMRI's suite of integrated drug discovery solutions, which includes medicinal chemistry, high content imaging, cell-based assays, high-throughput screening and screening by mass spectrometry.

“Ion channels are a class of well-validated drug targets. Many ion channels are linked to human disease by known disease-causing mutations in human,”​ said Kathy Bove, VP of global drug discovery business development at AMRI.

Further, there are numerous approved drugs that target ion channels, several of which have reached blockbuster status, she explained.

“Novel findings linking ion channels to other diseases and new technology approaches to find drugs effecting ion channel function make this an exciting class of targets for future drug discovery,” ​Bove told us. 

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more